Treatment ( DrugBank: - )

2 diseases

ID	Disease name (Link within this page)	Number of trials
41	Giant cell arteritis	57
299	Cystic fibrosis	288

41. Giant cell arteritis

Clinical trials : 131 / Drugs : 139 - (DrugBank : 36) / Drug target genes : 33 - Drug target pathways : 125

diseases per page:

Showing 1 to 10 of 57 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05380453 (ClinicalTrials.gov)	September 21, 2022	22/2/2022	Efficacy and Safety of Secukinumab in Patients With New Onset of Giant Cell Arteritis Who Are in Cli ...	A Randomized, Parallel-group, Double-blind, Placebo-controlled, Multicenter Trial to Investigate the ...	Giant Cell Arteritis	Biological: Secukinumab 300 mg, s.c.;Drug: Placebo to match Secukinumab, s.c.	Novartis Pharmaceuticals	NULL	Recruiting	50 Years	N/A	All	146	Phase 3	Germany
2	EUCTR2021-002528-18-DK (EUCTR)	22/02/2022	30/07/2021	RESCUE - Effect of supplemental hydrocortisone during stress in prednisolone-induced adrenal insuffi ...	RESCUE - Effect of supplemental hydrocortisone during stress in prednisolone-induced adrenal insuffi ...	Glucocorticoid-induced adrenal insufficiency MedDRA version: 20.0;Level: LLT;Classification code 100 ...	Trade Name: Hydrokortison orion Product Name: hydrokortison Product Code: H02AB09 INN or Proposed INN: ...	Copenhagen University Hospital Rigshospitalet	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	325	Phase 4	Denmark
3	NCT04474847 (ClinicalTrials.gov)	March 15, 2021	13/7/2020	Abatacept for the Treatment of Giant Cell Arteritis	A Randomized Double-Blind, Placebo Controlled Trial of Abatacept (CTLA4-Ig) in Giant Cell Arteritis ...	Giant Cell Arteritis	Drug: Abatacept;Drug: Placebo	University of Pennsylvania	NULL	Active, not recruiting	50 Years	N/A	All	78	Phase 3	United States;Canada
4	EUCTR2020-000622-26-DE (EUCTR)	22/01/2021	17/09/2020	A Proof-of-Concept Study of Guselkumab in the Treatmentof Subjects with New-Onset or Relapsing Giant ...	A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Proof-of-Concept Study to Eval ...	Giant Cell Arteritis MedDRA version: 23.1;Level: PT;Classification code 10018250;Term: Giant cell ar ...	Product Name: Guselkumab Product Code: CNTO1959 INN or Proposed INN: Guselkumab Product Name: Guselkuma ...	Janssen-Cilag International N.V.	NULL	Not Recruiting			Female: yes Male: yes	60	Phase 2	United States;France;Canada;Spain;Poland;Belgium;Israel;Germany;Italy
5	EUCTR2020-000622-26-IT (EUCTR)	18/12/2020	24/05/2021	A Proof-of-Concept Study of Guselkumab in the Treatmentof Subjects with New-Onset or Relapsing Giant ...	A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Proof-of-Concept Study to Eval ...	Giant Cell Arteritis MedDRA version: 23.1;Level: PT;Classification code 10018250;Term: Giant cell ar ...	Product Name: Guselkumab Product Code: [CNTO1959] INN or Proposed INN: GUSELKUMAB Other descriptive nam ...	JANSSEN CILAG INTERNATIONAL NV	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	60	Phase 2	France;United States;Canada;Spain;Poland;Belgium;Germany;Italy
6	NCT04633447 (ClinicalTrials.gov)	December 10, 2020	6/11/2020	A Study to Evaluate Guselkumab for the Treatmentof Participants With New-onset or Relapsing Giant Ce ...	A Phase 2, Multicenter, Randomized, Placebo-controlled, Double-blind, Proof-of-Concept Study to Eval ...	Giant Cell Arteritis	Drug: Guselkumab;Drug: Placebo	Janssen Research & Development, LLC	NULL	Recruiting	50 Years	N/A	All	51	Phase 2	United States;Belgium;Canada;France;Germany;Israel;Italy;Poland;Spain
7	NCT04239196 (ClinicalTrials.gov)	July 1, 2020	19/11/2019	Efficacy of Tocilizumab for the Treatment of Acute AION Related to GCA	Open Label Phase II Randomized Non-comparative Study of SC Tocilizumab Associated With IV Pulse Ster ...	Giant Cell Arteritis;Optic Ischaemic Neuropathy	Drug: tocilizumab and IV steroids combination;Other: IV steroids combination alone	Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts	Roche Chugai	Not yet recruiting	50 Years	N/A	All	58	Phase 2	France
8	NCT05394909 (ClinicalTrials.gov)	February 7, 2020	20/5/2022	Ultra-short Glucocorticosteroids and Tocilizumab Therapy in GCA Patients	TreatmentOf Giant Cell Arteritis Patients With Ultra-short Glucocorticosteroids And tociliZumab: Rol ...	GCA;TOCILIZUMAB;Glucocorticoids;PET	Drug: Tocilizumab 162Mg/0.9Ml Autoinjector	Azienda Unità Sanitaria Locale Reggio Emilia	NULL	Active, not recruiting	N/A	N/A	All	20		Italy
9	NCT03892785 (ClinicalTrials.gov)	January 27, 2020	26/3/2019	MEthotrexate Versus TOcilizumab for Treatmentof GIant Cell Arteritis: a Multicenter, Randomized, Con ...	MEthotrexate Versus TOcilizumab for Treatmentof GIant Cell Arteritis: a Multicenter, Randomized, Con ...	Giant Cell Arteritis	Drug: Prednisone treatment;Drug: Tocilizumab treatment;Drug: Methotrexate treatment;Other: Questionn ...	Centre Hospitalier Universitaire Dijon	NULL	Recruiting	50 Years	N/A	All	230	Phase 3	France
10	EUCTR2018-001003-36-HR (EUCTR)	10/04/2019	17/05/2019	A clinical study to test treatment of KPL-301 compared to placebo in giant cell arteritis	A Phase 2, randomized, double-blind placebo-controlled study to test the efficacy and safety of KPL- ...	giant cell arteritis MedDRA version: 20.0;Level: LLT;Classification code 10018250;Term: Giant cell a ...	Product Name: Mavrilimumab Product Code: KPL-301 INN or Proposed INN: MAVRILIMUMAB Other descriptive na ...	Kiniksa Pharmaceuticals, Ltd. (Hamilton, Bermuda) c/o Kiniksa Pharmaceuticals Corp.	NULL	Not Recruiting			Female: yes Male: yes	60	Phase 2	United States;Serbia;Estonia;Slovenia;Spain;Ireland;United Kingdom;Italy;Belgium;Poland;Croatia;Aust ...

First Previous1 2 3 4 5 6Next Last

299. Cystic fibrosis

Clinical trials : 1,695 / Drugs : 1,527 - (DrugBank : 268) / Drug target genes : 111 - Drug target pathways : 174

diseases per page:

Showing 1 to 10 of 288 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05408910 (ClinicalTrials.gov)	July 2023	2/6/2022	Rifaximin for Treatment of Bloating in Children and Adults With Cystic Fibrosis	Rifaximin for Treatment of Bloating in Children and Adults With Cystic Fibrosis	Cystic Fibrosis;Abdominal Pain;Small Bowel Disease	Drug: Rifaximin 550 MG Oral Tablet [XIFAXAN];Drug: Placebo	Wake Forest University Health Sciences	Emory University;University of Minnesota;University of Texas Southwestern Medical Center	Not yet recruiting	12 Years	N/A	All	100	Phase 2/Phase 3	United States
2	NCT05581056 (ClinicalTrials.gov)	February 24, 2023	12/10/2022	Evaluation of the Evolution of Quality of Life in Relation to Naso-sinus Symptomatology Under Treatm ...	Evaluation of the Evolution of Quality of Life in Relation to Naso-sinus Symptomatology Under Treatm ...	Cystic Fibrosis	Drug: CFTR modulators	Hospices Civils de Lyon	NULL	Not yet recruiting	6 Years	11 Years	All	90		France
3	NCT05641298 (ClinicalTrials.gov)	February 10, 2023	29/11/2022	Study to Determine the Efficacy&Safety of ARV-1801(ACG-701) for the Treatmentof Cystic Fibrosis Pulm ...	A Phase 2, Randomized, DB, Placebo-controlled Study to Determine the Efficacy, Safety and PK Profile ...	Cystic Fibrosis;Cystic Fibrosis Pulmonary Exacerbation	Drug: Sodium Fusidate;Drug: Placebo	Aceragen	NULL	Recruiting	12 Years	N/A	All	80	Phase 2	United States
4	NCT05548283 (ClinicalTrials.gov)	February 1, 2023	16/9/2022	Standardizing Treatments for Pulmonary Exacerbations - Aminoglycoside Study	Standardizing Treatments for Pulmonary Exacerbations: A Platform for Evaluating TreatmentDecisions t ...	Cystic Fibrosis;Cystic Fibrosis Pulmonary Exacerbation	Drug: Beta-lactam antibiotic;Drug: Aminoglycoside	Chris Goss	University of Washington;Medical University of South Carolina;Cystic Fibrosis Foundation	Not yet recruiting	6 Years	N/A	All	730	Phase 4	NULL
5	NCT05743946 (ClinicalTrials.gov)	February 2023	15/2/2023	Trikafta for Patients With Non-cystic Fibrosis Bronchiectasis	Evaluating Trikafta for the Treatment of Patients With Non-cystic Fibrosis Bronchiectasis (NCFBE)	Non-cystic Fibrosis Bronchiectasis	Drug: Trikafta	Emory University	The Marcus Foundation, Inc.	Recruiting	18 Years	N/A	All	30	Phase 4	United States
6	NCT05561764 (ClinicalTrials.gov)	January 3, 2023	27/9/2022	Imipenem/Cilastatin/Relebactam Pharmacokinetics, Safety, and Outcomes in Adults and Adolescents With ...	A Multicenter, Open-label Study to Determine the Pharmacokinetics, Safety, and Outcomes of Imipenem/ ...	Cystic Fibrosis;Pneumonia, Bacterial	Drug: Imipenem/Cilastatin/Relebactam	Hartford Hospital	Merck Sharp & Dohme LLC;Q2 Solutions;Connecticut Children's Medical Center;St. Christopher's Hospita ...	Recruiting	12 Years	N/A	All	16	Phase 4	United States
7	NCT05530278 (ClinicalTrials.gov)	September 20, 2022	5/9/2022	A Study to Assess the Pharmacokinetics and Safety of Co-administered Oral Galicaftor, Navocaftor, an ...	Assessment of Multiple-Dose Pharmacokinetics and Safety of the Co-administration of Galicaftor, Navo ...	Healthy Volunteers	Drug: Galicaftor;Drug: ABBV-576;Drug: Navocaftor;Drug: Midazolam	AbbVie	NULL	Completed	18 Years	65 Years	Female	24	Phase 1	United States
8	NCT05599230 (ClinicalTrials.gov)	September 1, 2022	21/10/2022	Daily Monitoring of Respiratory Symptoms and Spirometry During ETI Treatmentin Persons With Cystic F ...	Daily Monitoring of Respiratory Symptoms and Spirometry During ETI Treatmentin Persons With Cystic F ...	Cystic Fibrosis	Drug: Elexacaftor 100 MG / Ivacaftor 75 MG / Tezacaftor 50 MG, 2 tablets each morning + Ivacaftor 15 ...	CHC Montlegia	NULL	Active, not recruiting	12 Years	N/A	All	20		Belgium
9	NCT05095246 (ClinicalTrials.gov)	March 8, 2022	27/8/2021	A Study of Inhaled KB407 for the Treatment of Cystic Fibrosis	A Phase I Study of Inhaled KB407, a Replication-Incompetent, Non-Integrating Vector Expressing Human ...	Cystic Fibrosis	Biological: KB407 (Nebulization)	Krystal Biotech, Inc.	Novotech (Australia) Pty Limited	Recruiting	18 Years	N/A	All	13	Phase 1	Australia
10	EUCTR2020-005931-58-FR (EUCTR)	02/04/2021	04/02/2021	ACTIVE : ACid tranexamic or Terlipressin for Initial emergency treatmentof mild to seVere hEmoptysis ...	ACTIVE : ACid tranexamic or Terlipressin for Initial emergency treatmentof mild to seVere hEmoptysis ...	Hemoptysis, whatever the cause, with the exception of cystic fibrosis;Therapeutic area: Diseases [C] ...	Trade Name: GLYPRESSINE 1 mg/5 mL, poudre et solvant pour solution injectable (I.V.) INN or Proposed ...	ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	315	Phase 3	France

First Previous1 2 3 4 5…29Next Last